You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國醫藥(600056.SH):下屬公司產品注射用頭孢他啶及注射用更昔洛韋擬中標第五批全國藥品集採
格隆匯 06-23 19:05

格隆匯6月23日丨中國醫藥(600056.SH)公佈,2021年6月23日,公司下屬子公司海南通用三洋藥業有限公司(“通用三洋”)及湖北科益藥業股份有限公司(“科益藥業”)參加了第五批全國藥品集中採購的投標。根據聯合採購辦公室發佈的全國藥品集中採購擬中選結果公示顯示,通用三洋通過仿製藥質量和療效一致性評價的產品注射用頭孢他啶,及科益藥業通過一致性評價的產品注射用更昔洛韋擬中標此次集中採購。

注射用頭孢他啶擬中標0.5g、1.0g、2.0g三個規格,擬中標價格分別為67.65元/盒、115元/盒、195.5元/盒。注射用更昔洛韋擬中標0.25g、0.5g兩個規格,擬中標價格分別為203元/盒、345.1元/盒。

科益藥業此次擬中標產品注射用更昔洛韋2020年營業收入約為4,545萬元,約佔公司2020年度營業收入總額的0.12%;通用三洋此次擬中標產品注射用頭孢他啶2020年度無銷售。次擬中標的兩個產品首年約定中標數量收入約為7,217萬元,約佔公司2020年度營業收入總額的0.18%,預計不會對公司業績產生較大影響。

次集中採購是國家組織的第五批藥品集中帶量採購,採購週期中,醫療機構將優先使用此次集中採購中選品種,並確保完成約定採購量。若通用三洋及科益藥業確定中標,後續簽訂採購合同並實施後,將有利於進一步擴大相關產品的銷售,提高市場佔有率,促進兩家公司有關產品的市場開拓,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account